A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists.
Pancreatic cancer (PDAC) is one of the most aggressive solid tumors and is showing increasing incidence. The aim of our review is to provide practical help for all clinical oncologists and to summarize the current management of PDAC using a simple "ABC method" (A—anatomical resectability, B—biologic...
| Publicado en: | Current Oncology Vol. 30; no. 11; pp. 9587 - 9602 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Nov2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=173827215&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 173827215 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Nov2023 vid: 30 iid: 11 pid: 97109 pub: MDPI artinfo: ui: 173827215 10.3390/curroncol30110694 173827215 ppf: 9587 ppct: 15 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists. aug: au: Garajová, Ingrid Peroni, Marianna Gelsomino, Fabio Leonardi, Francesco affil: Medical Oncology Unit, University Hospital of Parma, 43125 Parma, Italy sug: ab: Pancreatic cancer (PDAC) is one of the most aggressive solid tumors and is showing increasing incidence. The aim of our review is to provide practical help for all clinical oncologists and to summarize the current management of PDAC using a simple "ABC method" (A—anatomical resectability, B—biological resectability and C—clinical conditions). For anatomically resectable PDAC without any high-risk factors (biological or conditional), the actual standard of care is represented by surgery followed by adjuvant chemotherapy. The remaining PDAC patients should all be treated with initial systemic therapy, though the intent for each is different: for borderline resectable patients, the intent is neoadjuvant; for locally advanced patients, the intent is conversion; and for metastatic PDAC patients, the intent remains just palliative. The actual standard of care in first-line therapy is represented by two regimens: FOLFIRINOX and gemcitabine/nab-paclitaxel. Recently, NALIRIFOX showed positive results over gemcitabine/nab-paclitaxel. There are limited data for maintenance therapy after first-line treatment, though 5-FU or FOLFIRI after initial FOLFIRINOX, and gemcitabine, after initial gemcitabine/nab-paclitaxel, might be considered. We also dedicate space to special rare conditions, such as PDAC with germline BRCA mutations, pancreatic acinar cell carcinoma and adenosquamous carcinoma of the pancreas, with few clinically relevant remarks. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|